|
Regeneron, Sanofi asthma drug seen as potential game changer
Reuters (Reuters) – A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease, researchers … Monoclonal antibody appears effective and safe in asthma Phase IIa trial Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of … |
View full post on asthma – Google News